- Home
- BAFN vs FHTX Comparison
BAFN vs FHTX Comparison
Compare BAFN & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BAFN | FHTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 173.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BAFN | FHTX |
|---|---|---|
| Price | $5.13 | $1.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.17 |
| AVG Volume (30 Days) | 172.1K | ★ 1.1M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $4.26 | $1.79 |
| 52 Week High | $10.18 | $7.61 |
Technical Indicators
Market Signals| Indicator | BAFN | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.81 | 15.02 |
| Support Level | $4.53 | $1.79 |
| Resistance Level | $6.75 | $5.35 |
| Average True Range (ATR) | 0.67 | 0.25 |
| MACD | -0.31 | -0.04 |
| Stochastic Oscillator | 10.71 | 2.07 |
Price Performance
Historical ComparisonAbout BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company that operates through its wholly owned subsidiary. The Company generates the majority of its revenue from interest on loans and noninterest income. The primary sources of funding for its loans are loan payments, deposits, and borrowings. It is dependent on noninterest income, which is derived from net gain on the sales of the guaranteed portion of government-guaranteed loans and service fee income. The company provides personal banking and business banking services.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.